- Home
- VFL vs SGMO Comparison
VFL vs SGMO Comparison
Compare VFL & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFL
- SGMO
- Stock Information
- Founded
- VFL 1993
- SGMO 1995
- Country
- VFL United States
- SGMO United States
- Employees
- VFL N/A
- SGMO N/A
- Industry
- VFL Finance/Investors Services
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VFL Finance
- SGMO Health Care
- Exchange
- VFL Nasdaq
- SGMO Nasdaq
- Market Cap
- VFL 116.3M
- SGMO 122.8M
- IPO Year
- VFL N/A
- SGMO 2000
- Fundamental
- Price
- VFL $10.23
- SGMO $0.68
- Analyst Decision
- VFL
- SGMO Strong Buy
- Analyst Count
- VFL 0
- SGMO 7
- Target Price
- VFL N/A
- SGMO $5.29
- AVG Volume (30 Days)
- VFL 38.0K
- SGMO 5.4M
- Earning Date
- VFL 01-01-0001
- SGMO 11-11-2025
- Dividend Yield
- VFL 4.16%
- SGMO N/A
- EPS Growth
- VFL N/A
- SGMO N/A
- EPS
- VFL N/A
- SGMO N/A
- Revenue
- VFL N/A
- SGMO $81,706,000.00
- Revenue This Year
- VFL N/A
- SGMO $28.47
- Revenue Next Year
- VFL N/A
- SGMO N/A
- P/E Ratio
- VFL N/A
- SGMO N/A
- Revenue Growth
- VFL N/A
- SGMO 565.52
- 52 Week Low
- VFL $7.93
- SGMO $0.41
- 52 Week High
- VFL $10.77
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- VFL 61.64
- SGMO 66.82
- Support Level
- VFL $10.11
- SGMO $0.65
- Resistance Level
- VFL $10.34
- SGMO $0.73
- Average True Range (ATR)
- VFL 0.09
- SGMO 0.06
- MACD
- VFL -0.02
- SGMO 0.02
- Stochastic Oscillator
- VFL 38.71
- SGMO 67.74
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.